Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8657 |
High Similarity |
NPD3027 |
Phase 3 |
0.8649 |
High Similarity |
NPD4966 |
Approved |
0.8649 |
High Similarity |
NPD4967 |
Phase 2 |
0.8649 |
High Similarity |
NPD4965 |
Approved |
0.8571 |
High Similarity |
NPD37 |
Approved |
0.8473 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8411 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.8182 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.8153 |
Intermediate Similarity |
NPD7228 |
Approved |
0.8074 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8074 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.8062 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.8 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7971 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.797 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7962 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.795 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7943 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7943 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.7867 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7842 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7786 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7756 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7755 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.766 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7593 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7582 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7552 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7536 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7533 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7532 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7518 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7485 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7448 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7419 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.741 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7394 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7383 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7383 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7368 |
Intermediate Similarity |
NPD228 |
Approved |
0.7368 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7368 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.7343 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7342 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7342 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7333 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7315 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.731 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7305 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7303 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7297 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.7289 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7285 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7285 |
Intermediate Similarity |
NPD4237 |
Approved |
0.7279 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.7261 |
Intermediate Similarity |
NPD7028 |
Phase 2 |
0.7246 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7218 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7218 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7208 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7192 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7188 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7185 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7183 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7174 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD3384 |
Approved |
0.717 |
Intermediate Similarity |
NPD3382 |
Approved |
0.717 |
Intermediate Similarity |
NPD3383 |
Approved |
0.717 |
Intermediate Similarity |
NPD1934 |
Approved |
0.716 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7152 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7152 |
Intermediate Similarity |
NPD4675 |
Approved |
0.7143 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7143 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7135 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7133 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7125 |
Intermediate Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD3892 |
Phase 2 |
0.7124 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7123 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7117 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7111 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7108 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7095 |
Intermediate Similarity |
NPD2238 |
Phase 2 |
0.7078 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7075 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7075 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7075 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD3060 |
Approved |
0.7059 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD5177 |
Phase 3 |
0.7048 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7048 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7047 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7047 |
Intermediate Similarity |
NPD5735 |
Approved |
0.7024 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.702 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7019 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7019 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7013 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7006 |
Intermediate Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.6994 |
Remote Similarity |
NPD4055 |
Discovery |
0.6974 |
Remote Similarity |
NPD2161 |
Phase 2 |
0.6963 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.6954 |
Remote Similarity |
NPD4536 |
Approved |
0.6954 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6954 |
Remote Similarity |
NPD6841 |
Approved |
0.6954 |
Remote Similarity |
NPD6842 |
Approved |
0.6954 |
Remote Similarity |
NPD4538 |
Approved |
0.6933 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6928 |
Remote Similarity |
NPD5763 |
Approved |
0.6928 |
Remote Similarity |
NPD5762 |
Approved |
0.6923 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6914 |
Remote Similarity |
NPD8455 |
Phase 2 |
0.6899 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD8651 |
Approved |
0.6892 |
Remote Similarity |
NPD7095 |
Approved |
0.689 |
Remote Similarity |
NPD5604 |
Discontinued |
0.6875 |
Remote Similarity |
NPD1608 |
Approved |
0.6875 |
Remote Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.687 |
Remote Similarity |
NPD1242 |
Phase 1 |
0.6867 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6867 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6867 |
Remote Similarity |
NPD4140 |
Approved |
0.686 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6857 |
Remote Similarity |
NPD7243 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD7097 |
Phase 1 |
0.6842 |
Remote Similarity |
NPD6895 |
Approved |
0.6842 |
Remote Similarity |
NPD6896 |
Approved |
0.6839 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6832 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6828 |
Remote Similarity |
NPD3685 |
Discontinued |
0.6826 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6826 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6824 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.6824 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6821 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6821 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6821 |
Remote Similarity |
NPD230 |
Phase 1 |
0.6813 |
Remote Similarity |
NPD4210 |
Discontinued |
0.681 |
Remote Similarity |
NPD7819 |
Suspended |
0.681 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6806 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6803 |
Remote Similarity |
NPD4624 |
Approved |
0.68 |
Remote Similarity |
NPD554 |
Clinical (unspecified phase) |
0.68 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD5960 |
Phase 3 |
0.6795 |
Remote Similarity |
NPD7466 |
Approved |
0.6795 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6794 |
Remote Similarity |
NPD3020 |
Approved |
0.6792 |
Remote Similarity |
NPD7526 |
Approved |
0.6792 |
Remote Similarity |
NPD52 |
Approved |
0.6792 |
Remote Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.679 |
Remote Similarity |
NPD5089 |
Approved |
0.679 |
Remote Similarity |
NPD5090 |
Approved |
0.6786 |
Remote Similarity |
NPD3926 |
Phase 2 |
0.6786 |
Remote Similarity |
NPD709 |
Approved |
0.6786 |
Remote Similarity |
NPD5242 |
Approved |
0.6783 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6783 |
Remote Similarity |
NPD2667 |
Approved |
0.6783 |
Remote Similarity |
NPD5846 |
Approved |
0.6783 |
Remote Similarity |
NPD2668 |
Approved |
0.6781 |
Remote Similarity |
NPD1283 |
Approved |
0.6776 |
Remote Similarity |
NPD6653 |
Approved |
0.6774 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD5297 |
Approved |
0.6772 |
Remote Similarity |
NPD1511 |
Approved |
0.6768 |
Remote Similarity |
NPD2563 |
Approved |
0.6768 |
Remote Similarity |
NPD2560 |
Approved |
0.6759 |
Remote Similarity |
NPD2232 |
Approved |
0.6759 |
Remote Similarity |
NPD2230 |
Approved |
0.6759 |
Remote Similarity |
NPD2233 |
Approved |
0.6753 |
Remote Similarity |
NPD6099 |
Approved |
0.6753 |
Remote Similarity |
NPD2438 |
Suspended |
0.6753 |
Remote Similarity |
NPD6100 |
Approved |
0.6752 |
Remote Similarity |
NPD6190 |
Approved |
0.6752
|
Remote Similarity |
NPD5241 |
Discontinued |